New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors
NTRK fusions are oncogenic drivers in a variety of tumors. The Food and Drug Administration has recently approved the NTRK inhibitors larotrectinib and entrectinib for the treatment of pediatric and adult patients with NTRK fusion positive advanced solid tumors regardless of tumor histology.
In children, the incidence of NTRK fusions is high (more than 90 percent) in certain tumors, such as infantile fibrosarcoma, congenital mesoblastic nephroma, and secretory carcinoma; lower (between 5 percent and 26 percent) in other tumors such as pediatric papillary thyroid carcinomas and a subset of pediatric gliomas; and rarely seen in different acute leukemia.
In this webinar, Marilyn M. Li of the Children’s Hospital of Philadelphia will discuss a study of a large cohort of pediatric tumors using custom-designed DNA- and RNA-based next-generation sequencing panels. The team found that NTRK fusions are more common in pediatric tumors compared to adult tumors and involve a broader panel of fusion partners and a wider range of tumors than previously recognized.
The identification of these NTRK fusions is essential for precise tumor diagnosis and accurate tumor treatment. Therefore, it is crucial to include NTRK fusions as part of tumor genomic profiling for pediatric cancer patients to facilitate pediatric precision cancer care.
For Research Use Only. Not for use in diagnostics procedures.
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Marilyn M. Li